Welcome to our dedicated page for Innate Pharma Sa news (Ticker: IPHA), a resource for investors and traders seeking the latest updates and insights on Innate Pharma Sa stock.
Innate Pharma S.A. (IPHA) news covers the company’s progress as a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. As a dual-listed issuer on Euronext Paris (IPH) and Nasdaq (IPHA), Innate Pharma regularly publishes regulatory and corporate updates that are relevant to investors following immuno-oncology and antibody-based therapeutics.
News about Innate Pharma frequently highlights developments across its antibody-engineering and ANKET® (Antibody-based NK cell Engager Therapeutics) platform. Company releases describe clinical and regulatory milestones for key assets such as IPH4502, a differentiated Nectin-4 ADC in solid tumors; lacutamab, a first-in-class anti-KIR3DL2 monoclonal antibody in cutaneous and peripheral T cell lymphomas; and monalizumab, an anti-NKG2A antibody developed in collaboration with AstraZeneca in non-small cell lung cancer.
Investors can expect updates on clinical trial progress, including Phase 1, Phase 2 and Phase 3 studies, regulatory designations for pipeline assets, and collaboration news involving partners such as Sanofi and AstraZeneca. Innate Pharma’s news flow also includes financial communications, such as business updates, financial results, financial calendars, and regulatory disclosures on the number of shares outstanding and voting rights under French market rules.
This news page aggregates these company communications in one place, making it easier to follow Innate Pharma’s clinical pipeline evolution, partnership activities and key corporate events. Readers interested in immuno-oncology, antibody-drug conjugates, NK cell engagers and collaboration-driven biotech models can use this feed to monitor how Innate Pharma reports its progress over time.
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) announced participation in investor conferences, including Citi's 17th Annual BioPharma Conference on September 7-8, 2022, and H.C. Wainwright's 24th Annual Global Investment Conference from September 12-14, 2022. The company, focused on oncology, is advancing several first-in-class therapeutic antibodies aimed at enhancing cancer treatment outcomes. With a strong pipeline and partnerships with major biopharmaceutical leaders, Innate is committed to improving patient care in high unmet medical need areas.
Innate Pharma has released its total number of shares outstanding and voting rights as of August 1, 2022. The company has 79,893,019 ordinary shares and 6,514 preferred shares from 2016 and 7,581 from 2017. The total theoretical voting rights stand at 80,650,859, with exercisable voting rights at 80,632,284. This disclosure is in compliance with French regulations to ensure transparency for shareholders.
Innate Pharma announced that the INTERLINK-1 Phase 3 study, sponsored by AstraZeneca, did not meet the efficacy threshold during an interim analysis and will be discontinued. The trial evaluated monalizumab with cetuximab against cetuximab alone for patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Despite this setback, Innate remains optimistic about monalizumab's potential in lung cancer and continues to focus on ongoing studies like PACIFIC-9 and NeoCOAST-2. AstraZeneca will share data from the trial in the future.
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) has announced participation in the upcoming BTIG Biotechnology Conference scheduled for August 8-9, 2022 in New York. The company is focused on developing therapeutic antibodies to improve oncology treatments. With a diverse pipeline of clinical and preclinical candidates, Innate is recognized for its expertise in Natural Killer cell biology and partnerships with major biopharmaceutical companies such as Bristol-Myers Squibb and AstraZeneca. For more information, visit www.innate-pharma.com.
Innate Pharma has announced that Sanofi is progressing IPH6401/SAR’514 into investigational new drug enabling studies, triggering a €3 million milestone payment. This BCMA-targeting NK cell engager utilizes Sanofi’s CROSSODILE platform, combined with Innate’s ANKET technology, to enhance NK cell activation for cancer therapy. IPH6401/SAR’514 has demonstrated anti-tumor activity in preclinical models, with Sanofi overseeing its development, manufacturing, and commercialization. The collaboration may yield up to €400 million in further development milestones and royalties for Innate.
Innate Pharma SA (Euronext: IPH; Nasdaq: IPHA) announced its participation in the Portzamparc Corporate Access event in Paris on June 30, 2022. The company is a clinical-stage biotech firm focused on oncology, aiming to improve cancer treatments through antibody therapies that utilize the immune system. Innate has a diverse pipeline of clinical candidates and partnerships with leading pharmaceutical companies, including Bristol-Myers Squibb and AstraZeneca. Headquartered in Marseille, France, Innate continues to advance its research and collaboration efforts.
Innate Pharma announced that its anti-CD39 monoclonal antibody, IPH5201, will advance to a Phase 2 clinical trial in lung cancer. The company will receive a
Innate Pharma (Euronext: IPH; Nasdaq: IPHA) has announced the results of its Annual General Meeting (AGM) held on May 20, 2022, in Marseille, France. A quorum of 40.88% was reached with 134 votes cast from a total of 32,598,725 shares. Notably, Dr. Sally Bennett has been appointed to the Supervisory Board and will also serve on the Audit Committee. She brings over 20 years of experience in finance and life sciences. Additionally, Mr. Patrick Langlois has resigned from the Board after 12 years of service.
Innate Pharma SA (Euronext: IPH; Nasdaq: IPHA), a clinical-stage biotech company focused on oncology, announced participation in key investor conferences. The H.C. Wainwright Annual Global Life Sciences Conference will take place from May 23-25, 2022, followed by Citi’s European Healthcare Conference on June 16, 2022. Innate Pharma aims to enhance cancer treatment through innovative antibodies targeting the immune system, supported by collaborations with major biopharmaceutical companies. The company is headquartered in Marseille, France, with a US office in Rockville, MD.
Innate Pharma (IPHA) announced significant progress in its clinical pipeline, highlighted by the first patient dosed in AstraZeneca's Phase 3 clinical trial, PACIFIC-9, triggering a $50 million milestone payment. This will enhance the company's cash position to €131.7 million as of March 31, 2022. Revenue for Q1 2022 was €2.6 million, down from €4.5 million year-over-year, primarily from collaboration agreements. The company is optimistic about future clinical milestones and updates on its diverse pipeline of immuno-oncology treatments.